Strategies for pneumococcal vaccination in older adults in the coming era

References

• Kobayashi M, Pilishvili T, Farrar JL, Leidner AJ, Gierke R, Prasad N, Moro P, Campos-Outcalt D, Morgan RL, Long SS, et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the advisory committee on immunization practices, United States, 2023. MMWR Recomm Rep. 2023;72(3):1–6. doi:10.15585/mmwr.rr7203a1.
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Amaro R, Torres A. Pneumococcal vaccination. Curr Opin Infect Dis. 2016;29(2):187–96. doi:10.1097/QCO.0000000000000246.
   PubMed Web of Science ®Google Scholar
• Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, et al. Theory and strategy for pneumococcal vaccines in the elderly. Hum Vaccin Immunother. 2016;12:336–43. doi:10.1080/21645515.2015.1075678.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Peeters CC, van den Dobbelsteen GP. The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines. 2013;12(12):1379–94. doi:10.1586/14760584.2013.852475.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: updated recommendations of the advisory committee on immunization practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–17. doi:10.15585/mmwr.mm7104a1.
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5.
   PubMed Web of Science ®Google Scholar
• Chandler T, Furmanek S, Carrico R, Balcom D, Arnold F, Ramirez J. 23-valent pneumococcal polysaccharide vaccination does not prevent community-acquired pneumonia hospitalizations due to vaccine-type streptococcus pneumoniae. Microorganisms. 2022;10(3):560. doi:10.3390/microorganisms10030560.
   PubMed Web of Science ®Google Scholar
• Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, Sundaraiyer V, Peng Y, Moyer L, Pride MW, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clin Infect Dis. 2022;75(3):390–8. doi:10.1093/cid/ciab990.
   PubMed Web of Science ®Google Scholar
• Song JY, Chang CJ, Andrews C, Diez-Domingo J, Oh MD, Dagan R, Hartzel J, Pedley A, Li J, Sterling T, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: a randomized phase III trial (PNEU-PATH). Vaccine. 2021;39(43):6422–36. doi:10.1016/j.vaccine.2021.08.038.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Minute of the meeting held on 07 June 2023. [accessed 2024 Jan 7]. https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/1262409204637.
   Google Scholar
• Wierzbowski A, Pless R, Hildebrand KJ. Summary of the NACI statement on public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines. Can Commun Dis Rep. 2023;49(2/3):81–6. doi:10.14745/ccdr.v49i23a08.
   PubMedGoogle Scholar
• Haute Autorité de Santé. Stratégie de vaccination contre les infections à pneumocoque - Place du vaccin pneumococcique polyosidique conjugué (20-valent, adsorbé) chez l’adulte. [ accessed 2024 Jan 25]. https://www.has-sante.fr/jcms/p_3457419/fr/strategie-de-vaccination-contre-les-infections-a-pneumocoque-place-du-vaccin-pneumococcique-polyosidique-conjugue-20-valent-adsorbe-chez-l-adulte#ancreDocAss.
   Google Scholar
• Aktuelle daten und informationen zu infektionskrankheiten und public health Epidemiologisches Bulletin 39/2023. [accessed 2024 Jan 7]. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/39_23.pdf?__blob=publicationFile.
   Google Scholar
• Noharet-Koenig R, Lasota K, Faivre P, Langevin E. Evolution of pneumococcal vaccine recommendations and criteria for decision making in 5 Western European countries and the United States. MDM Policy Pract. 2023;8(1):238146832311744. doi:10.1177/23814683231174432.
   Google Scholar
• Nakashima K, Suzuki K, Aoshima M, Murabata M, Kondo K, Ohfuji S, Fukushima W, Maeda A, Hirota Y. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: a multicenter hospital-based case-control study in Japan. Vaccine. 2022;40:6589–98. doi:10.1016/j.vaccine.2022.09.055.
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;CD000422. doi:10.1002/14651858.CD000422.pub3.
   PubMedGoogle Scholar
• Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Jamalkandi SA, Ahmadi A. Pneumococcal disease and the effectiveness of the PPV23 vaccine in adults: a two-stage Bayesian meta-analysis of observational and RCT reports. Sci Rep. 2018;8(1):11051. doi:10.1038/s41598-018-29280-2.
   PubMedGoogle Scholar
• Farrar JL, Childs L, Ouattara M, Akhter F, Britton A, Pilishvili T, Kobayashi M. Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults. Pathogens. 2023;12:732. doi:10.3390/pathogens12050732.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Yamaryo T, Oishi K. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28:7063–9. doi:10.1016/j.vaccine.2010.08.010.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D’Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ (Clin Res Ed). 2010;340(mar08 1):c1004–c. doi:10.1136/bmj.c1004.
   PubMedGoogle Scholar
• Suzuki K, Kondo K, Washio M, Nakashima K, Kan S, Imai S, Yoshimura K, Ota C, Ohfuji S, Fukushima W, et al. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study. Hum Vaccines Immunother. 2019;15(9):2171–7. doi:10.1080/21645515.2019.1584023.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–21. doi:10.1016/S1473-3099(17)30049-X.
   PubMed Web of Science ®Google Scholar
• Shoji H, Maeda M, Shirakura T, Takuma T, Hanaki H, Niki Y. Changes in the distribution of capsular serotypes of streptococcus pneumoniae isolated from adult respiratory specimens in Japan. Intern Med. 2015;54(11):1337–41. doi:10.2169/internalmedicine.54.3845.
   PubMed Web of Science ®Google Scholar
• Katoh S, Suzuki M, Ariyoshi K, Morimoto K. Serotype replacement in adult pneumococcal pneumonia after the introduction of seven-valent pneumococcal conjugate vaccines for children in Japan: a systematic literature review and pooled data analysis. Jpn J Infect Dis. 2017;70(5):495–501. doi:10.7883/yoken.JJID.2016.311.
   PubMed Web of Science ®Google Scholar
• Ubukata K, Takata M, Morozumi M, Chiba N, Wajima T, Hanada S, Shouji M, Sakuma M, Iwata S. Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010–2017. Emerg Infect Dis. 2018;24:2010–20. doi:10.3201/eid2411.180326.
   PubMed Web of Science ®Google Scholar
• Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K, et al. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: the Japan Pneumococcal Vaccine Effectiveness study (J-PAVE). Vaccine. 2019;37(20):2687–93. doi:10.1016/j.vaccine.2019.04.009.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older us adults: a test-negative design. Clin Infect Dis. 2018;67:1498–506. doi:10.1093/cid/ciy312.
   PubMed Web of Science ®Google Scholar
• Heo JY, Seo YB, Choi WS, Kim EJ, Jeong HW, Lee J, Yoon JG, Noh JY, Cheong HJ, Kim WJ, et al. Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study. J Infect Dis. 2021;225:836–45. doi:10.1093/infdis/jiab474.
   Web of Science ®Google Scholar
• Patterson S, Webber C, Patton M, Drews W, Huijts SM, Bolkenbaas M, Gruber WC, Scott DA, Bonten MJM. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 2016;5:92–6. doi:10.1016/j.trivac.2016.04.004.
   Google Scholar
• Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, Hall-Murray CK, Jodar L, Isturiz RE. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018;36:1477–83. doi:10.1016/j.vaccine.2018.01.049.
   PubMed Web of Science ®Google Scholar
• Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, Andrews NJ. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. E Clin Med. 2018;6:42–50. doi:10.1016/j.eclinm.2018.12.007.
   Google Scholar
• Dunne EM, Cilloniz C, von Mollendorf C, Lewnard J, Grant LR, Slack MPE, Jodar L, Theilacker C, Gessner BD. Pneumococcal vaccination in adults: what can we learn from observational studies that evaluated PCV13 and PPV23 effectiveness in the same population? Arch Bronconeumol. 2023;59:157–64. doi:10.1016/j.arbres.2022.12.015.
   PubMed Web of Science ®Google Scholar
• Maeda H, Gopal Dhoubhadel B, Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, et al. Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: two multicenter observational studies from 2011 to 2020. Vaccine. 2022;40(37):5504–12. doi:10.1016/j.vaccine.2022.07.041.
   PubMed Web of Science ®Google Scholar
• Grant LR, Begier E, Theilacker C, Barry R, Hall-Murray C, Yan Q, Pope V, Pride MW, Jodar L, Gessner BD, et al. Multicountry review of streptococcus pneumoniae serotype distribution among adults with community-acquired pneumonia. J Infect Dis. 2024;229(1):282–93. doi:10.1093/infdis/jiad379.
   PubMed Web of Science ®Google Scholar
• Torres A, Menéndez R, España PP, Fernández-Villar JA, Marimón JM, Cilloniz C, Méndez R, Egurrola M, Botana-Rial M, Ercibengoa M, et al. The evolution and distribution of pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Spain using a serotype-specific urinary antigen detection test: the CAPA study, 2011–2018. Clin Infect Dis. 2021;73(6):1075–85. doi:10.1093/cid/ciab307.
   PubMed Web of Science ®Google Scholar
• Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert RR, Jodar L, Gessner BD. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Vaccine. 2023;41:5662–9. doi:10.1016/j.vaccine.2023.08.001.
   PubMed Web of Science ®Google Scholar
• Isturiz R, Grant L, Gray S, Alexander-Parrish R, Jiang Q, Jodar L, Peyrani P, Ford KD, Pride MW, Self WH, et al. Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults. Clin Infect Dis. 2021;73(7):1216–22. doi:10.1093/cid/ciab375.
   PubMed Web of Science ®Google Scholar
• Hoshi SL, Shono A, Seposo X, Okubo R, Kondo M. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Vaccine. 2022;40(49):7057–64. doi:10.1016/j.vaccine.2022.10.010.
   PubMed Web of Science ®Google Scholar
• Song JY, Choi JY, Lee JS, Bae I-G, Kim YK, Sohn JW, Jo YM, Choi WS, Lee J, Park KH, et al. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis. 2013;13(1):202. doi:10.1186/1471-2334-13-202.
   PubMed Web of Science ®Google Scholar
• Chen H, Matsumoto H, Horita N, Hara Y, Kobayashi N, Kaneko T. Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis. Sci Rep. 2021;11(1):11865. doi:10.1038/s41598-021-91234-y.
   PubMed Web of Science ®Google Scholar
• Chan T, Tay MZ, Kyaw WM, Chow A, Ho HJ. Epidemiology, vaccine effectiveness, and risk factors for mortality for pneumococcal disease among hospitalised adults in Singapore: a case-control study. BMC Infect Dis. 2020;20(1):423. doi:10.1186/s12879-020-05140-1.
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Wunderink RG, Christiani DC, Cormier SA, Crothers K, Doerschuk CM, Evans SE, Goldstein DR, Khatri P, Kobzik L, et al. Future research directions in pneumonia. NHLBI working group report. Am J Respir Crit Care Med. 2018;198:256–63. doi:10.1164/rccm.201801-0139WS.
   PubMed Web of Science ®Google Scholar
• Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. Physiol Rev. 2018;98(3):1417–64. doi:10.1152/physrev.00032.2017.
   PubMed Web of Science ®Google Scholar
• Kato T, Miyashita N, Kawai Y, Horita N, Yano S, Oka Y, Oda T, Okimoto N. Changes in physical function after hospitalization in patients with nursing and healthcare-associated pneumonia. J Infect Chemother. 2016;22:662–6. doi:10.1016/j.jiac.2016.06.005.
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang C-C, Newman A, Loehr L, Folsom AR, Elkind MS, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264–74. doi:10.1001/jama.2014.18229.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Cohen AL, Poehling KA, Hardin CC. The present and future of the adult pneumococcal vaccine program in the United States. NEJM Evid. 2023;2(11):EVIDra2300221. doi:10.1056/EVIDra2300221.
   PubMedGoogle Scholar
• McLaughlin JM, Swerdlow DL, Isturiz RE, Jodar L. Decision-making for PCV in adults. Hum Vaccin Immunother. 2019;15:584–93. doi:10.1080/21645515.2018.1538611.
   PubMed Web of Science ®Google Scholar
• Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia. 2022;14(1):14. doi:10.1186/s41479-022-00097-y.
   Web of Science ®Google Scholar
• Li S, Liang H, Zhao S-H, Yang X-Y, Guo Z. Recent progress in pneumococcal protein vaccines. Front Immunol. 2023;14:14. doi:10.3389/fimmu.2023.1278346.
   Web of Science ®Google Scholar